Chen et al revealed that right-sided tumor site was an independent predictor of shorter PFS (HR = 1.32, P = 0.0072) and OS (HR = 1.45, P = 0.0003) among 969 patients with KRAS wild-type CRC receiving Cetuximab therapy treatment[26]. The gene discussed is KRAS; the disease is neoplasm.